Core Viewpoint - Maplight Therapeutics (MPLT.US) has successfully launched on the US stock market, with shares rising over 15.8% to $19.7, following an IPO price of $17, indicating strong market interest in its innovative approach to treating central nervous system disorders [1] Company Overview - Maplight Therapeutics was founded by renowned leaders in psychiatry and neuroscience, focusing on addressing the lack of targeted drug therapies for specific neural circuits in patients [1] - The company has developed a platform capable of identifying neural circuits causally related to diseases, allowing for targeted therapeutic modulation [1] Product Pipeline - Maplight has created a range of candidate products aimed at treating some of the most challenging central nervous system diseases, including schizophrenia, Alzheimer's disease, and autism spectrum disorders [1]

Core Insights - Maplight Therapeutics (MPLT.US) has successfully launched on the US stock market, with shares rising over 15.8% to $19.7, after an IPO price of $17 [1] Company Overview - Maplight Therapeutics was founded by renowned leaders in psychiatry and neuroscience, focusing on addressing the lack of targeted drug therapies for specific neural circuits [1] - The company claims its platform can identify neural circuits causally related to diseases and provide therapeutic modulation for these circuits [1] Product Development - Maplight has developed a range of candidate products aimed at treating some of the most challenging central nervous system diseases, including schizophrenia, Alzheimer's disease, and autism spectrum disorders [1]